Brensocatib Named FDA Breakthrough Therapy for Non-CF Bronchiectasis
News
Insmed’s brensocatib has been granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA) for the treatment of adults with non-cystic fibrosis bronchiectasis. The designation is given to investigational ... Read more